Maternal SSRI Use and Neonatal Withdrawal Syndrome: Recognition and Management

Introduction: Maternal Depression, SSRIs, and Neonatal Impact

Depression affects approximately 10-20% of pregnant women worldwide, with Indian studies reporting prevalence rates of 15-25% depending on the population studied. Selective serotonin reuptake inhibitors (SSRIs) are the most commonly prescribed antidepressants during pregnancy, with exposure rates of 2-8% in developed countries. In India, while SSRI prescription during pregnancy is lower, increasing awareness of perinatal mental health is leading to rising prescribing rates, particularly in urban tertiary care settings.

The clinical dilemma lies in balancing the established risks of untreated maternal depression, including preterm birth, low birth weight, impaired maternal-infant bonding, and postpartum complications, against the potential neonatal effects of SSRI exposure, most notably poor neonatal adaptation syndrome (PNAS). This guide provides an evidence-based framework for understanding, recognizing, and managing neonatal SSRI withdrawal, with specific attention to the Indian clinical context.

Pharmacology of SSRIs in Pregnancy

Placental Transfer and Fetal Exposure

All SSRIs cross the placenta, with varying degrees of fetal exposure depending on the specific agent's pharmacokinetic properties. The placental transfer ratio (fetal-to-maternal serum concentration) determines the degree of neonatal serotonergic exposure.

SSRI	Placental Transfer Ratio	Half-Life (hours)	Active Metabolites	Relative PNAS Risk
Fluoxetine	0.6-0.8	72-360 (with norfluoxetine)	Yes (norfluoxetine)	Moderate (prolonged)
Paroxetine	0.3-0.5	21	No	Highest
Sertraline	0.3-0.4	26	Weak (desmethylsertraline)	Lower
Citalopram	0.5-0.7	35	Weak	Moderate
Escitalopram	0.5-0.7	27-32	Weak	Moderate

Serotonergic Effects on Fetal Development

Serotonin plays crucial roles in fetal neurodevelopment beyond its adult neurotransmitter function. It serves as a trophic factor during brain development, influencing neuronal migration, differentiation, myelination, and synaptogenesis. SSRI exposure during the third trimester, when synaptogenesis peaks, alters serotonergic tone in the developing brain. The consequences include adaptation of fetal serotonin receptor density (downregulation), altered serotonin transporter expression, and modified autonomic nervous system development, all of which contribute to PNAS when the exogenous serotonergic stimulus is abruptly removed at birth.

Poor Neonatal Adaptation Syndrome: Clinical Presentation

Incidence and Timing

PNAS occurs in approximately 25-30% of neonates exposed to SSRIs in the third trimester, though mild symptoms may be present in up to 70% with systematic assessment. Symptom onset typically occurs within 24-48 hours of birth, with the timing reflecting the specific SSRI's half-life. Paroxetine withdrawal presents earliest (within hours) due to its short half-life, while fluoxetine-related symptoms may be delayed by several days due to the prolonged half-life of its active metabolite norfluoxetine.

Clinical Features of PNAS

The syndrome encompasses three domains of symptoms: neurological, respiratory, and gastrointestinal. Differentiating PNAS from neonatal sepsis is a critical clinical challenge.

• Neurological symptoms: Tremors (most common), irritability, high-pitched cry, jitteriness, sleep disturbance, hypertonicity or hypotonia, seizures (rare, less than 1%)
• Respiratory symptoms: Tachypnea, nasal congestion, respiratory distress, rarely persistent pulmonary hypertension of the newborn (PPHN)
• Gastrointestinal symptoms: Feeding difficulty, poor suck, vomiting, diarrhea, poor weight gain
• Autonomic symptoms: Temperature instability, diaphoresis, mottling, hypoglycemia

PNAS vs Serotonin Syndrome vs Withdrawal

The pathophysiology of PNAS remains debated. Two mechanisms are proposed: serotonergic discontinuation syndrome (withdrawal from chronic SSRI exposure) and serotonin toxicity (excess serotonergic activity). In practice, most cases likely involve a combination of both mechanisms, with withdrawal predominating for short-acting agents like paroxetine and serotonergic excess more relevant for fluoxetine, whose active metabolite persists in the neonatal circulation for weeks.

Assessment and Scoring of Neonatal SSRI Withdrawal

Modified Finnegan Neonatal Abstinence Scoring

While the Finnegan Neonatal Abstinence Scoring System was developed for opioid withdrawal, it has been adapted for SSRI-related PNAS assessment. Scoring is performed every 4-8 hours for the first 48-72 hours in all SSRI-exposed neonates. Key scored parameters include the following.

1. CNS disturbances: Cry quality (high-pitched, continuous), sleep duration after feeding, Moro reflex (hyperactive), tremors (with or without stimulation), increased muscle tone, and excoriation
2. Metabolic and vasomotor: Sweating, fever, mottling, nasal stuffiness, sneezing, nasal flaring
3. Gastrointestinal: Excessive sucking, poor feeding, regurgitation, loose stools

Scores of 8 or above on three consecutive assessments indicate significant PNAS requiring enhanced supportive care. Scores consistently above 12 may indicate need for pharmacological intervention, though this is rarely required for SSRI withdrawal.

Differential Diagnosis

Before attributing symptoms to PNAS, the following conditions must be excluded through appropriate investigations, particularly in the Indian context where infectious etiologies are prevalent.

Differential Diagnosis	Key Differentiating Features	Investigations
Neonatal sepsis	Fever or hypothermia, lethargy, poor perfusion	Blood culture, CRP, CBC, procalcitonin
Hypoglycemia	Jitteriness, seizures, poor feeding	Blood glucose (bedside and laboratory)
Neonatal hypocalcemia	Tremors, seizures, QT prolongation	Serum calcium, ionized calcium, ECG
Neonatal thyrotoxicosis	Tachycardia, irritability, exophthalmos	TSH, free T4, maternal thyroid history
Concomitant opioid withdrawal	Polydrug exposure history	Maternal drug screening, meconium toxicology

Management of Neonatal SSRI Withdrawal

Non-Pharmacological Interventions (First-Line)

The vast majority of PNAS cases respond to supportive non-pharmacological care, which should be the foundation of management for all affected neonates.

• Skin-to-skin contact (Kangaroo Mother Care): Reduces stress hormones, stabilizes temperature and heart rate, and promotes breastfeeding. NNF India strongly endorses KMC for SSRI-exposed neonates.
• Demand breastfeeding: SSRIs are excreted in breast milk at low concentrations, providing a gradual weaning effect that eases withdrawal. Sertraline has the lowest breast milk transfer and is preferred if SSRI continuation is planned postpartum.
• Swaddling and minimal stimulation: Reduces sensory overload that exacerbates neurological symptoms. A quiet, dimly lit environment with clustered care minimizes disturbance.
• Small, frequent feeds: Addresses poor feeding tolerance and prevents hypoglycemia. Caloric supplementation may be needed if weight loss exceeds 7-10% in the first week.
• Gentle handling protocols: Staff education on minimizing stimulation, positioning techniques, and non-nutritive sucking (pacifier use) to reduce irritability.

Pharmacological Treatment (Rarely Required)

Pharmacological intervention is reserved for severe cases with persistent high Finnegan scores despite adequate non-pharmacological support. When needed, options include low-dose phenobarbital (loading 10-15 mg/kg, maintenance 3-5 mg/kg/day) for severe tremors and seizures, and rarely, low-dose chlorpromazine for extreme irritability. Unlike opioid NAS, morphine is not appropriate for SSRI withdrawal unless concurrent opioid exposure is documented.

SSRI-Specific Considerations and Comparative Safety

Paroxetine: Highest PNAS Risk

Paroxetine carries the highest risk of PNAS among SSRIs, with some studies reporting symptoms in up to 30-40% of exposed neonates. Its short half-life (21 hours) means neonatal drug levels fall rapidly after birth, precipitating acute withdrawal. Additionally, paroxetine has been associated with a small increased risk of cardiac malformations (particularly ventricular septal defects) when used in the first trimester, leading to its FDA reclassification from Category C to Category D. FOGSI and ACOG recommend switching to sertraline when initiating or changing antidepressant therapy during pregnancy.

Fluoxetine: Prolonged but Milder Symptoms

Fluoxetine's active metabolite norfluoxetine has a half-life exceeding 7 days in neonates, providing a built-in tapering effect that reduces acute withdrawal severity. However, serotonergic effects may persist for 2-4 weeks postnatally. Fluoxetine has the most extensive safety data in pregnancy and remains a reasonable choice when other SSRIs are unavailable, as is sometimes the case in Indian public health settings.

Sertraline: Preferred for Breastfeeding

Sertraline has the lowest breast milk excretion among SSRIs, with infant serum levels typically undetectable. This makes it the preferred agent when both antepartum treatment and breastfeeding continuation are planned. The PNAS risk is moderate, and the intermediate half-life provides a reasonable balance between withdrawal severity and symptom duration.

Indian Clinical Context

Perinatal Mental Health in India

Perinatal depression in India faces significant underrecognition and undertreatment. Cultural stigma around mental illness, lack of trained perinatal psychiatrists, and limited screening implementation mean that many Indian women with perinatal depression remain untreated. The National Mental Health Programme and FOGSI have initiated efforts to integrate mental health screening into routine antenatal care using validated tools like the Edinburgh Postnatal Depression Scale (EPDS).

SSRI Availability and Prescribing Patterns in India

Fluoxetine and sertraline are available as generic formulations across India at affordable prices (INR 2-5 per tablet). Escitalopram and paroxetine are also widely available. Indian prescribing data suggests that fluoxetine is the most commonly prescribed SSRI in pregnancy, followed by sertraline. Specialist psychiatric input for dose adjustment and medication selection during pregnancy is limited outside metropolitan centers, making clinical guidelines particularly important for primary care and obstetric practitioners.

Persistent Pulmonary Hypertension of the Newborn

A controversial association exists between late-pregnancy SSRI exposure and persistent pulmonary hypertension of the newborn (PPHN). Initial studies suggested a 6-fold increased risk, but subsequent larger studies have shown much smaller effect sizes (OR 1.5-2.1). The absolute risk remains very low, estimated at 3-6 per 1000 exposed neonates compared to 1-2 per 1000 unexposed. When PPHN does occur, echocardiographic assessment, oxygen therapy, and sometimes inhaled nitric oxide are required. HEAMAC neonatal monitoring protocols include guidance for post-discharge cardiorespiratory surveillance after SSRI-related PPHN.

Monitoring and Follow-Up Protocol

A structured monitoring and follow-up approach is recommended for all SSRI-exposed neonates.

1. Delivery room: Alert neonatal team of SSRI exposure, drug name, dose, and duration. Routine neonatal resuscitation readiness.
2. First 48 hours: Finnegan scoring every 4-8 hours, blood glucose monitoring, respiratory assessment, and feeding evaluation.
3. 48-72 hours: If scores remain below 8 and feeding is established, consider discharge with follow-up plan.
4. 1-2 week follow-up: Assess feeding, weight gain, sleep patterns, and resolution of withdrawal symptoms.
5. 3-6 month follow-up: Developmental screening, particularly motor milestones and social-emotional development. HEAMAC neonatal care resources support structured developmental follow-up for exposed neonates.

Conclusion: Evidence-Based SSRI Management in Pregnancy

Maternal SSRI use during pregnancy requires a nuanced risk-benefit analysis. Untreated maternal depression poses substantial risks to both mother and neonate, while SSRI-related PNAS, though common, is generally mild and self-limiting. The key clinical principles are: avoid paroxetine when possible, prefer sertraline for breastfeeding mothers, maintain the lowest effective dose, prepare the neonatal team for withdrawal symptoms, and implement structured Finnegan scoring with primarily non-pharmacological management. In India, strengthening perinatal mental health services while building neonatal capacity for PNAS management will ensure that both maternal wellbeing and neonatal safety are optimized.